Mereo BioPharma Group plc
MREO evidence brief
What we can confirm
- BioSniper Score:
- 9.3 / 10
- Market Cap:
- $44.7M
- Lead Asset:
- alvelestat (Phase 3)
What it means
What to watch
Prepared research question
What matters most for MREO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MREO
Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases, with lead programs in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) and osteogenesis imperfecta (OI).
Key risk: Limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$44.7M
Cash Runway
—
Lead Asset
alvelestat (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates for Mereo BioPharma Group plc.
Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases, with lead programs in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) and osteogenesis imperfecta (OI).
- Cash and cash equivalents of $30.1 million as of June 30, 2026, expected to fund operations into late-2027 [sec].
- Entered into an option and license agreement with Sentynl Therapeutics for alvelestat in AATD-LD [news · 2026-08-11].
- Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta completed; additional data analyses ongoing [news · 2026-01-12].
- Received orphan designation for alvelestat for the treatment of AATD from the European Commission [sec · filed 2025-04-08].
- Completed a $50 million underwritten registered direct financing, extending cash runway into 2027 [sec · filed 2025-04-08].
What works
- Mereo has a strategy of acquiring product candidates with substantial pre-clinical, clinical, and manufacturing data packages from large pharmaceutical companies, reducing early-stage risk [sec_mda · as of 2026-08-11].
- The company has successfully completed large, randomized Phase 2 trials for four product candidates and the Phase 1b portion of a Phase 1b/2 for a fifth [sec_mda · as of 2026-08-11].
- Alvelestat has received orphan designation from the European Commission for AATD, which may provide regulatory and commercial advantages [sec · filed 2025-04-08].
- A partnership with Sentynl Therapeutics for alvelestat provides a potential path for development and commercialization in AATD-LD [news · 2026-08-11].
What to weigh
- Mereo reported no revenue and a net loss of $7.0 million for the quarter ended June 30, 2026, reflecting its clinical-stage status [sec].
- Cash and cash equivalents of $30.1 million as of June 30, 2026, provide a limited runway into late-2027, requiring future financing to sustain operations [sec].
- The setrusumab program in osteogenesis imperfecta faces uncertainty, with additional data analyses ongoing to determine the potential path forward [news · 2026-01-12].
- The company is dependent on the success of its rare disease pipeline, which is subject to high clinical and regulatory risks [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Cash position and runway
“Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027”
News · August 11, 2026
Partnership for alvelestat
“Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)”
News · August 11, 2026
Setrusumab program status
“Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program”
News · January 12, 2026
Orphan designation for alvelestat
“receipt of orphan designation for the treatment of AATD from the European Commission”
SEC filings · April 8, 2025
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $30.1M as of June 30, 2026, expected to fund operations only into late-2027, requiring additional financing [sec].
- No approved products or revenue — Mereo reported zero revenue and a net loss of $7.0M for Q2 2026, typical for a clinical-stage company [sec].
- Setrusumab program uncertainty — Phase 3 data analyses for setrusumab in OI are ongoing, with no clear path forward yet [news · 2026-01-12].
- Dependence on rare disease pipeline — The company's success hinges on clinical and regulatory outcomes for a few rare disease candidates [sec_mda · as of 2026-08-11].
What to watch
- Further updates on the setrusumab program in osteogenesis imperfecta, expected by year-end 2026 [news · 2026-08-11].
- Progress of the alvelestat Phase 3 program in AATD-LD, including protocol submission and trial initiation [sec · filed 2025-04-08].
- Cash runway management and potential future financing needs as the company approaches late-2027 [sec].
- Regulatory interactions with agencies regarding setrusumab's potential path forward [news · 2026-08-11].
Sources: News · SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run Mereo BioPharma Group plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mereo BioPharma Group plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.21 · 0% dilution
Lead: Phase 3
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 1, 2026- % of float
- 6.4%
- Days to cover
- 5.3
- Shares short
- 8,267,481
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MREO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mereo BioPharma Group plc?
Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases, with lead programs in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) and osteogenesis imperfecta (OI).
What is Mereo BioPharma Group plc's lead drug candidate?
Mereo BioPharma Group plc's most advanced tracked candidate is alvelestat (Phase 3) for Severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Who is the CEO of Mereo BioPharma Group plc?
Dr. Denise Vera Scots-Knight Ph.D. is the chief executive officer of Mereo BioPharma Group plc (MREO).
Where is Mereo BioPharma Group plc headquartered?
Mereo BioPharma Group plc (MREO) is headquartered in London, United Kingdom.
What therapeutic areas does Mereo BioPharma Group plc focus on?
Mereo BioPharma Group plc develops therapies across Oncology, Respiratory, Musculoskeletal, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.